Patricia is a Principal for AmorChem. She plays a key role in the elaboration and management of technical maturation plans which produce the data required to confirm the commercial potential of AmorChem’s drug discovery projects. Her experience helps her to define important milestones and to support academic research teams as they transition into the drug discovery space. She has overseen several successful AmorChem projects, most notably SEMA3A, which led to the spinning off of SemaThera and eventually attracted Roche as a major collaborator.
She joined the AmorChem team as a Project Manager in 2013 and became Director, Project Management. Patricia previously gained 15 years of industry experience acquired in the pharmaceutical sector as well as in biotechnology and academic settings. Indeed, she spent 11 years at AstraZeneca R&D Montreal where she was involved in the drug discovery process. Prior to AstraZeneca, she worked at Procyon BioPharma and at McGill University. Patricia obtained an MSc in neurology and neurosurgery from McGill University.